Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study.

Those with highly significant correlations P < 0.01 between the outcome measures of Group A are (1) right eye RNFL with the third-ventricle volume, (2) PSQI sleep quality with the right-lateral-ventricle, (3) left eye RNFL with left-cerebral white matter volume, (4) PSQI sleep quality with left-lateral-ventricle, (5) right eye RNFL with PSQI sleep latency, (6) PSQI sleep latency with left thalamus volume, (7) right-cerebral white matter volume with MS disease duration, (8) SF-36 pain with third-ventricle volume, (9) SF-36 (social functioning) with PSQI sleep quality, (10) PSQI sleep medications with MS disease duration.

also in 93,232 other papers

In contrast, Group A patients showed a significant improvement in general health (SF-36) at 3- and 6-month time points, while Group B self-reported a positive trend at 12 months.

also in 7,469 other papers